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Study objectives: Diffuse parenchymal lung disease is associated with a high risk of
mortality despite early referral and listing for lung transplantation. We hypothesized
that cardiopulmonary exercise test results and the distance walked in 6min (6MWTD)
would be associated with survival in patients with diffuse parenchymal lung disease
referred for lung transplantation.
Design: Retrospective cohort study.
Setting: Tertiary care center.
Patients: We included 51 consecutive patients with diffuse parenchymal lung
disease who underwent exercise testing after referral to the Lung Transplant
Program at the New York Presbyterian Hospital between January 2000 and December
2002. Thirty-three patients were listed, and 7 underwent transplantation during the
study period. There were 17 deaths with 1 death post-transplantation.
Results: A 6MWTD o350m was associated with an increased risk of death
(HR ¼ 4.6, 95% CI 1.5–14.2, P ¼ 0:009). Oxygen saturation with unloaded exercise
(HR ¼ 0.91, 95% CI 0.84–0.98, P ¼ 0:015) and oxygen consumption at peak exerciseElsevier Ltd. All rights reserved.
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TS, American Thoracic Society; CI, confidence interval; ROC, receiver operating characteristic;
rbon dioxide; VO2/HR, oxygen pulse
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S.M. Kawut et al.1432adjusted for weight (HR ¼ 0.88, 95% CI 0.79–0.99, P ¼ 0:039) were also associated
with the risk of death. A patient with oxygen saturation o95% during unloaded
exercise had a 75% chance of dying on the list for transplantation. A patient with
6MWTD o350m had a 67% chance of dying on the list.
Conclusions: Cardiopulmonary exercise test parameters and the 6MWTD were
associated with the risk of death. Measures during exercise may be useful for
determination of prognosis and for prioritizing patients with diffuse parenchymal
lung disease for lung transplantation.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Interstitial lung disease has recently been reclassi-
fied as
’ ’
diffuse parenchymal lung disease’’
(DPLD).1 Many forms of DPLD are associated with
a poor prognosis and high risk of mortality. Although
certain types of DPLD respond to medical therapy,
lung transplantation often is the only viable
therapeutic option. Unfortunately, patients with
DPLD have a higher risk of death on the waiting list
compared to that of patients with other diagnoses.2
Although lung function, histology, and radiographic
appearance have been associated with outcomes in
patients with usual interstitial pneumonia (UIP),3–9
these parameters are not necessarily valid in a
broader cohort of patients with DPLD referred for
transplantation after failure of medical therapies.
Patients with DPLD often demonstrate an abnormal
cardiopulmonary response to exercise. The limitation
to exercise in DPLD is multifactorial, incorporating
cardiac, ventilatory, vascular, and muscular compo-
nents. Cardiopulmonary exercise testing (CPET)
measures these determinants of exercise perfor-
mance and may shed light on the physiologic
mechanisms of morbidity and mortality in DPLD.
Although the 6min walk test also quantifies exercise
performance, this test provides less information
regarding specific limiting factors and is therefore
considered complementary to CPET.10 The clinical
role of CPETand the 6min walk test in the assessment
of prognosis in patients with DPLD is unclear.10–14
We hypothesized that CPET results and the
distance walked in 6min (6MWTD) would be asso-
ciated with survival in patients with advanced DPLD.
We also assessed the ability of CPET and 6MWTD to
discriminate listed patients who died before receiv-
ing a lung transplant from those who were alive on
the list or who received lung transplants.Methods and materials
Study subjects and design
We performed a retrospective cohort study of
consecutive patients with DPLD who underwentCPET after referral to the Lung Transplant Program
at New York Presbyterian Hospital between January
2000 and December 2002. Patients with a diagnosis
of idiopathic interstitial pneumonia or DPLD of
known cause using standard criteria1 and evalua-
tion for lung transplantation with CPET between
January 2000 and December 2002 were included.
Patients with previous evaluation for lung trans-
plantation at another center or other forms of DPLD
(e.g., sarcoid) were excluded. The study was
approved by the Western Institutional Review
Board.Methods
We collected data including patient demographics,
spirometry, lung volumes, diffusion capacity for
carbon monoxide (DLCO), and hemodynamic mea-
surements from right heart catheterization. Pul-
monary hypertension was defined by mean
pulmonary artery pressure425mmHg. Two pulmo-
nologists (S.M.A. and S.M.K.) independently as-
signed diagnoses according to American Thoracic
Society (ATS) guidelines, which incorporate diag-
nostic criteria with or without lung biopsy.1
Disagreements were resolved by consensus. Primary
outcomes included (1) all-cause mortality and (2)
death on the waiting list for transplantation. We
assessed outcomes through chart review and search
of the Social Security Death Index. A patient was
considered to be alive at the last medical contact
noted in the chart if it was within 3 months of the
completion of the study period (February 15, 2003).
For patients who were not seen in the previous 3
months, the referring physicians were contacted
for follow-up.
CPET was performed on a single bicycle erg-
ometer (Ergometrics 800, Sensormedics Inc., Yorba
Linda, CA) with a metabolic cart (Sensormedics
Vmax 229, Sensormedics Inc., Yorba Linda, CA).
Patients receiving supplemental home oxygen
therapy or who had room air oxygen saturation
o90% (N ¼ 31) were exercised with 30% fractional
oxygen via mouthpiece. After 5min of rest on the
ergometer, subjects underwent unloaded pedaling
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Exercise testing in lung fibrosis 1433for 3min. We used an established ramp watt
protocol for exercise testing with 5, 10, or 15W/
min testing. During all subject testing, we mon-
itored continuous 12-Lead telemetry (Marquette
Max-1), and oxygen saturation by pulse oximetry
(Sensormedics Sat-Trak). Oxygen consumption
(VO2) and carbon dioxide production (VCO2) were
calculated on a breath-by-breath basis with 20-s
averaging. Recovery measurements were recorded
at one minute after maximal exercise. The anae-
robic threshold (AT) was determined using the V-
Slope method of analysis. Reference values for
CPET were calculated from standard sources.11,15
Six minute walk testing was performed (N ¼ 43)
with (N ¼ 25) or without (N ¼ 18) supplemental
oxygen, as recommended by ATS guidelines.10Analysis
Continuous variables were summarized by the
mean7standard deviation or median (range).
Categorical variables were summarized by the
frequency (95% confidence interval (CI)). Unpaired
t-tests, Wilcoxon rank-sum tests, chi-square tests,
and Fisher’s exact tests were used, as appropriate.
We performed two distinct analyses to address
the two different aims of the study. First, we used
Cox proportional hazards regression to identify
predictors of time-to-death.16 The hazard ratios
derived from these models are similar to the
relative risks of death when comparing patients.
We constructed individual models with lung trans-
plantation as a time-dependent covariate. This
analysis
’ ’
controls’’ for receiving a transplant (or
eliminates this as a factor) to understand if there
are CPET parameters reflecting cardiac or muscu-
loskeletal limitation which may be associated with
survival even if the patient proceeds to lung
transplantation. Others have used a similar meth-
odology to study patients with pulmonary fibrosis
undergoing lung transplantation.17,18
In a second analysis, we attempted to define
optimal cutoffs for variables which were associated
with dying on the waiting list for transplantation.
This methodology is based only on (1) whether a
patient died waiting for lungs or (2) was alive at the
end of the study or underwent lung transplanta-
tion. We assessed continuous variables from the
previous analyses with receiver operating charac-
teristic (ROC) curves. Areas (95% CI) under the ROC
curves were calculated. Cutpoints which maxi-
mized sensitivity and specificity were selected.
In the proportional hazards models, nonlinearity
of continuous variables was assessed, and transfor-
mations or cutpoints were chosen based on optimalmodel fit. The proportional hazards assumption was
examined for all significant predictors using
Schoenfeld residuals and tests based on weighted
residuals.19 Variables which did not meet this
assumption were included in the models with
interaction terms with time. We evaluated the
data for potentially influential observations using
delta–beta statistics. P values o0.05 were con-
sidered statistically significant. Stata 7.0 (College
Station, TX) was used for all analyses.Results
We identified 51 consecutive patients who met
eligibility criteria for this study. Twenty-eight (55%)
patients had UIP, and 4 (8%) additional patients had
UIP pattern with collagen vascular disease. Other
diagnoses included non-specific interstitial pneu-
monia (6), hypersensitivity pneumonitis (2), des-
quamative interstitial pneumonia (1), cryptogenic
organizing pneumonia (1), lymphoid interstitial
pneumonia (1), asbestosis (1), and unclassifiable
interstitial pneumonia (7). Thirty-five (69%) pa-
tients in the cohort had undergone surgical lung
biopsy. Patients with any missing exercise data
(N ¼ 10) were not significantly different from
patients with complete data in terms of age,
gender, race, and survival (all P40:10).
Demographic, pulmonary function and hemody-
namic data are summarized in Table 1. Patients
who died were more likely to be black or Hispanic
and had lower DLCO and higher pulmonary artery
pressures than patients who lived. 6WMTD and
CPET measurements at peak exercise are shown in
Table 2. Patients who died had lower 6MWTD, peak
work, and peak oxygen saturation than those who
were alive. Reasons for stopping exercise during
CPET included dyspnea in 31, fatigue in 21, dry
mouth in 1, and other in 2. Missing CPET data
resulted when one patient removed the pulse
oximeter at maximal exercise, and one patient
dismounted the cycle ergometer before recovery
measurements could be taken. As only 55% of the
cohort achieved AT, we limited our subsequent
analyses to unloaded, peak, and 1-min recovery
measurements.
Predictors of patient survival
Survival at one year from evaluation with CPETwas
72% (95% CI, 54–84%) for the entire cohort (includ-
ing post-transplant survival). Seven patients under-
went lung transplantation during the study period.
There were 17 deaths in our cohort with 1 death
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Table 1 Demographics, pulmonary function tests, and pulmonary artery pressures.
Characteristic All (n ¼ 51) Dead (n ¼ 17) Alive (n ¼ 34) P value
Sex (% male) 57 65 53 0.42
Race/ethnicity (% Black or Hispanic) 29 60 18 0.02
Age (years) 5378 5578 5379 0.44
FVC (L) 2.270.9 2.170.9 2.371.0 0.65
FVC (% pred) 55720 52718 57721 0.45
FEV1 (L) 1.870.7 1.870.7 1.870.7 0.84
FEV1 (% pred) 58720 57720 58720 0.91
TLC (L) 3.671.4 3.671.5 3.671.3 0.95
TLC (% pred) 61719 61722 61718 0.93
DLCO (mL/min/mm Hg) 8.774y 773 1074 0.003
DLCO (% pred) 31712y 2478 35712 0.002
MPAP (mmHg) 2279z 2779 1977 0.009
Pulmonary hypertension (%) 32z 57 19 0.03
Continuous variables expressed as mean 7 SD. P value for dead vs. alive.
N ¼ 41:
yN ¼ 46:
zN ¼ 40: FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; TLC: total lung capacity; DLCO: diffusion capacity
for carbon monoxide; mPAP: mean pulmonary artery pressure.
Table 2 6MWTD and CPET measurements at peak exercise.
Characteristic All (n ¼ 51) Dead (n ¼ 17) Alive (n ¼ 34) P value
6MWTD (m) 3457156* 2317120 4007142 0.0004
Work (watts) 63738 47735 71737 0.03
Heart rate (beats/min) 135719 135715 136721 0.91
Heart rate (% pred) 83711 8378 83713 0.96
SaO2 (%) 8875 8675 8975 0.02
VO2 (mL/min) 13657477 13267469 13857486 0.68
VO2 (% pred) 73733 69730 75735 0.51
VO2/kg (mL/min/kg) 1675 1573 1776 0.18
VO2 pulse (mL/min/beat) 1074 1074 1074 0.58
VE (L/min) 56721 58722 54721 0.40
RR (breaths/min) 50713 52713 49714 0.40
VE/VCO2 44713 48714 42712 0.06
Continuous variables expressed as mean 7 SD.
*N ¼ 43: 6MWTD: distance walked in 6min; SaO2: oxygen saturation; VO2: oxygen consumption; VE: minute ventilation; RR:
respiratory rate; VCO2: carbon dioxide production.
S.M. Kawut et al.1434post-transplant. Median follow-up was 271 (23–983)
days. Black race or Hispanic ethnicity, lower DLCO
% predicted, pulmonary hypertension, and a
6MWTD o350m (median) conferred an increased
risk of death even after
’ ’
controlling’’ for lung
transplantation (Table 3). Oxygen saturation
throughout CPET was inversely proportional to the
risk of death, as were peak VO2/kg and peak oxygen
pulse (VO2/HR). The results were unchanged afteradjusting for the use of supplemental oxygen during
the test. Patients who used supplemental oxygen
during CPET had a lower DLCO % predicted and a
higher mean pulmonary artery pressure than those
tested on room air (Po0:05).
There was a significant increase in risk for those
patients with peak or recovery ventilatory equiva-
lent for carbon dioxide (VE/VCO2)446 (the upper
quartile) (Po0:05). The risk associated with an
ARTICLE IN PRESS
Table 3 Predictors of death.
Variable Hazard ratio 95% CI P value
Race/ethnicity
Black/Hispanic 6.7 2.2–21 0.001
Other 1.0
DLCOy (% pred) 0.91 0.85–0.97 0.003
RAPz (5mmHg increase) 2.27 1.1–6.4 0.02
mPAPz (5mmHg increase) 1.6 1.1–2.2 0.006
Pulmonary hypertensionz
Present 6.7 2.0–22 0.002
Absent 1.0
6MWTD
o350m 4.6 1.5–14.2 0.009
X350m 1.0
Peak work (10W increase) 0.86 0.75–0.98 0.027
Time of exercise
o500 s 2.9 1.0–8.5 0.044
X500 s 1.0
SaO2
Unloaded 0.91 0.84–0.98 0.015
Peak 0.90 0.82–1.0 0.05
Recovery 0.82 0.73–0.92 0.001
VO2/kg: Peak 0.88 0.79–0.99 0.039
VO2/HR: Peak 0.03 0.001–0.098 0.049
VCO2: Unloaded 1.2 1.0–1.5 0.047
VE: Unloaded 1.04 1.01–1.07 0.003
DLCO: diffusion capacity for carbon dioxide; RAP: mean right atrial pressure; mPAP: mean pulmonary artery pressure; 6MWTD:
distance walked in six minutes; W: watts; SaO2: oxygen saturation; VO2: oxygen consumption; VO2/HR: oxygen pulse; VCO2:
carbon dioxide production; VE: minute ventilation.
yN ¼ 46:
zN ¼ 40:
N ¼ 43:
N ¼ 49:
Table 4 Prediction of death on the list for lung
transplantation.
Variable AUC 95% CI
SaO2, unloaded 0.89 0.74–1.0
6MWTD 0.87 0.72–1.0
Total exercise time 0.86 0.71–1.0
MPAP 0.81 0.62–1.0
Exercise testing in lung fibrosis 1435increased VE/VCO2 was non-proportional and in-
creased over time; therefore, this result could not
be estimated with a single HR or P value.
Subset analyses limited to patients with UIP
showed similar results. For example, patients with
UIP who walked o350m in 6min had more than 8
times the risk of death of those with UIP who
walked X350m in 6min.SaO2, resting 0.78 0.58–0.97
DLCO % predicted 0.76 0.56–0.96
AUC: area under the receiver operating characteristic
curve; SaO2: oxygen saturation; 6MWTD: distance walked
in 6min; mPAP: mean pulmonary artery pressure; DLCO:
diffusion capacity for carbon monoxide.Derivation of optimal clinical predictors for
’ ’
Death on the List’’
In the second analysis, we assessed variables which
distinguished patients who died on the list from
those who were alive or received a lung transplant.
We included listed patients with complete data
(N ¼ 25) (Table 4). An AUC of 1.0 indicates an ideal
test, which can perfectly discriminate between apatient who will die on the list while awaiting
lungs, and a patient who will remain alive. An AUC
of 0.50 is no better than chance; such a test has no
ARTICLE IN PRESS
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Figure 1 (a) Kaplan–Meier estimates of survival by
oxygen saturation during unloaded exercise. (b) Kaplan–
Meier estimates of survival by distance walked in 6min.
S.M. Kawut et al.1436ability to discriminate between patients who live
and those who die. A 95% CI which excludes 0.50
indicates a prognostic parameter which performs
better than chance.
We found that oxygen saturation with unloaded
exercise and 6MWTD were the best predictors. A
cutoff of oxygen saturation of o95% during
unloaded exercise had a sensitivity of 86% (95%
CI, 42–100%) and a specificity of 89% (95% CI,
65–99%) to predict death on the list. For a patient
with oxygen saturation of o95%, there was a 75%
chance of dying on the list. A patient with oxygen
saturation during unloaded exercise X95% would
have a 94% chance of being alive or receiving a lung
transplant. Similarly, a patient with a 6MWTD
o350m would have a 67% chance of dying on the
list. A patient with a 6MWTD X350m would have a
94% chance of being alive or receiving a lung
transplant. These results did not change after
adjusting for supplemental oxygen use during CPET.
There were significant differences in survival for
patients with low oxygen saturation during un-
loaded exercise or low 6MWTD using these cutoffs
in our entire cohort (Figs. 1a and b). There were
similar findings in the subset of patients with UIP
(Figs. 2a and b). Patients who underwent trans-
plantation were censored as alive in this analysis.
Model checking revealed reasonable fit of all of
the regression models. Although we identified a few
influential subjects for each regression coefficient,
deletion of these subjects from the data set and re-
analysis generally produced more dramatic, but
consistent, effect estimates for each statistically
significant predictor. In no case did these analyses
substantially change the effect estimates from the
full data set.Discussion
Functional assessment of patients with DPLD who
are evaluated for lung transplantation offers the
promise of improved risk stratification beyond that
provided by conventional measures of lung disease.
The recent ATS/ACCP Statement on Cardiopulmon-
ary Exercise Testing highlighted the potential of
CPET for determining prognosis in pulmonary
fibrosis, however, deemed this use of CPET to be
’ ’
controversial’’.11 The ATS has recommended 6min
walk testing for the prediction of mortality in
chronic obstructive pulmonary disease and primary
pulmonary hypertension, however, this committee
did not recommend the walk test for the prediction
of mortality in DPLD, likely due to insufficient
evidence.10 Our data show that VO2/kg, oxygensaturation, VE/VCO2, and 6MWTD are associated
with the risk of death in patients with DPLD who
were evaluated for lung transplantation.
We found that lower oxygen saturation during
exercise or recovery was associated with an
increased risk of death, similar to the findings of
others.5 Oxygen desaturation with exercise is
common in patients with DPLD.20,21 The potential
mechanisms of oxygen desaturation include V/Q
mismatching, diffusion limitation, intrapulmonary
shunt, low mixed venous oxygen saturation, and a
patent foramen ovale with right-to-left shunting of
deoxygenated blood. Considering these determi-
nants of systemic oxygen desaturation during
exercise, it is not surprising that this measure
was so strongly and consistently associated with
outcomes.
Patients who used supplemental oxygen during
testing had results similar to those of patients who
did not use supplemental oxygen. While this may be
unexpected, it appears that individuals who used
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Figure 2 (a) Kaplan–Meier estimates of survival in UIP by
oxygen saturation during unloaded exercise. (b) Kaplan–
Meier estimates of survival in UIP by distance walked in
6min.
Exercise testing in lung fibrosis 1437oxygen as outpatients (and therefore oxygen
during the testing) were more severely affected
than those who did not. It follows that the
same cutoff value of oxygen saturation predicts
an increased risk of death both in sicker patients
using supplemental oxygen and in healthier
patients who did not use oxygen therapy during
the testing.
Another important finding of our study was the
association of a reduced VO2/kg with an increased
risk of death. Systemic oxygen saturation, hemo-
globin level, oxyhemoglobin dissociation kinetics,
cardiac output, and tissue extraction factors affect
oxygen consumption. Collectively, these extra-
pulmonary aspects of chronic lung disease may
influence functional status and prognosis before
and after lung transplantation.22–24 Indeed, while
lung transplantation
’ ’
treats’’ the pulmonary com-
ponent of DPLD, systemic impairments in exerciseperformance persist.25,26 The primary inflammatory
disease process (or medications used to treat it)
may affect myocardial, diaphragmatic, vascular,
and peripheral muscular function, altering the
post-transplant course.
Inefficient ventilation (or increased VE/VCO2) at
peak exercise was associated with an increased risk
of death. Although this measure may reflect the
severity of parenchymal lung disease, there are
other interpretations.27 For example, patients with
primary pulmonary hypertension commonly have an
increased VE/VCO2 and an increased VE/VCO2
slope.28,29 These findings are thought to result
from V/Q mismatch, shunting of acidemic blood
through a patent foramen ovale, increased afferent
stimuli from the lungs or heart, and/or hypoxemia,
resulting in increased respiratory drive. Pulmonary
vascular disease in DPLD may increase both VE/
VCO2 and the risk of death, independent of the
parenchymal disease.22,30–32 This is supported by
the association of the risk of death with DLCO%
predicted and pulmonary artery pressures in our
cohort, but not with lung volumes or spirometry.
It would be useful to develop criteria to
distinguish patients with DPLD with a high risk of
death while awaiting lung transplantation. Other
studies of this issue differ from ours in several
ways.4–6,8,9,13,14,22 These cohorts included racially
and ethnically homogenous patient groups,
whereas almost 30% of our patients were black or
Hispanic, mirroring the demographics of the United
States.
Patients in our cohort had worse lung function
than that of patients in other studies.13,14 For
example, Lama et al. excluded patients with
resting hypoxemia on room air (only 15% of the
total cohort), while approximately 60% of the
patients in our cohort required oxygen at rest
(and therefore with exercise testing).13 These
differences in severity of illness and the use of
supplemental oxygen during walk testing likely
explain why oxygen desaturation predicted out-
come in other studies, whereas the 6MWTD
predicted outcome in ours.13,14
Lastly, some studies excluded outlying (or
’ ’
in-
fluential’’) subjects, whereas we included all
eligible patients, a conservative strategy reflecting
the clinical
’ ’
real-life’’ heterogeneity of this popu-
lation. A recent informative study of patients with
UIP excluded patients who eventually underwent
lung transplantation—an approach which limits its
applicability to our population of interest.3 While
others have shown the predictive value of 6min
walk testing in patients awaiting lung transplanta-
tion, the optimal prognostic parameter is not well-
defined in patients with DPLD.14,18,33
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S.M. Kawut et al.1438In our study, we found excellent sensitivity and
specificity of oxygen saturation o95% with un-
loaded exercise and 6MWTD o350m for prediction
of death on the list for patients with DPLD. For a
patient with oxygen saturation ofo95%, there was
a 75% chance of dying on the list. In a priority-based
lung allocation system, such a patient could be
given higher priority for lung transplantation, given
the otherwise dismal prognosis. Another patient
with oxygen saturation during unloaded exercise
X95% would have a 94% chance of being alive or
receiving a lung transplant—this patient could be
reassured that there was less urgency for immedi-
ate transplantation and could be monitored over
time. Similarly, a patient with a 6MWTD o350m
would have a 67% chance of dying on the list; such a
patient could be granted a
’ ’
high urgency’’ status
for transplantation. A patient with a 6MWTD
X350m would have a 94% chance of being alive
or receiving a lung transplant. This patient could be
given lower priority for lung transplantation and
managed expectantly. Although our findings rival
other published predictors of death in patients
awaiting transplantation, they need to be validated
before making firm recommendations.
We found an unexpected increased risk of death
for patients who were black or Hispanic, which
persisted despite adjustment for listing, transplan-
tation, DLCO % predicted, 6MWTD, or pulmonary
artery pressure (data not shown). The possible
presence of confounding by physiologic differences
or lead-time bias does not mitigate the fact that
patients who are black or Hispanic have a higher
risk of death after referral, regardless of listing and
transplantation status. If confirmed, these findings
should spur outreach and education regarding lung
transplantation for physicians with a high propor-
tion of black or Hispanic patients and the patients
themselves.
There are several limitations to our study. Our
source population, patterns of referral, transplant
waiting times, and cohort characteristics may
differ from those of other lung transplant pro-
grams. Confounding may be present, as a small
number of endpoints limited our ability to perform
extensive multivariate analyses. However, as most
of the physiologic variables in our analysis are in
the causal pathway, adjusting for these factors
would not necessarily be appropriate. Misclassifica-
tion of outcomes is unlikely, as we had a 0% loss to
follow-up rate. Although testing with supplemental
oxygen could alter the test performance, we did
not find significant changes in our results after
adjusting for oxygen use during testing. Many of
these patients were prescribed supplemental oxy-
gen for daily activities; performing maximal ex-ercise testing without prescribed therapy is neither
reasonable nor clinically useful.Conclusion
In summary, we have characterized CPET findings in
a cohort of patients with advanced DPLD referred
for lung transplantation. We have identified asso-
ciations between pulmonary hypertension, 6MWTD,
oxygen saturation during exercise, peak VO2/kg,
VO2/HR, and VE/VCO2 with outcomes. We have also
found oxygen saturation o95% during unloaded
exercise and 6MWTD o350m to be sensitive and
specific predictors of death on the transplant
waiting list. These results may elucidate the causes
of morbidity and mortality in DPLD. Furthermore,
considering the strong prognostic relationship with
survival, these measures may potentially serve as
surrogate endpoints for clinical trials of therapy for
DPLD. Lastly, validation of these CPET findings and
eventual incorporation into priority-based alloca-
tion algorithms for lung transplantation could
improve patient outcomes on the waiting list.Acknowledgements
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